Cadila Healthcare trades with traction on the bourses

20 Aug 2014 Evaluate

Cadila Healthcare is currently trading at Rs. 1217.00, up by 25.00 points or 2.10% from its previous closing of Rs. 1192.00 on the BSE.

The scrip opened at Rs. 1190.00 and has touched a high and low of Rs. 1221.00 and Rs. 1190.00 respectively. So far 5788 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1221.00 on 20-Aug-2014 and a 52 week low of Rs. 631.00 on 20-Aug-2013.

Last one week high and low of the scrip stood at Rs. 1221.00 and Rs. 1085.00 respectively. The current market cap of the company is Rs. 24617.94 crore.

The promoters holding in the company stood at 74.79% while Institutions and Non-Institutions held 14.19% and 11.01% respectively.

Cadila has received the final approval from the USFDA to market Acyclovir Tablets in the strengths of 400 mg and 800 mg. The drug falls under the anti-viral segment. The estimated sales in 2014 for Acyclovir Tablets is $55.8 million, as per IMS.

The group now has 95 approvals and has so far filed 249 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

 

Zydus Lifesciences Share Price

912.75 11.45 (1.27%)
31-Dec-2025 15:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1272.00
Cipla 1507.30
Zydus Lifesciences 912.75
Lupin 2112.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×